To assess the safety and tolerability and determine the Recommended phase 2 dose (RP2D) of JAB-3312 in combination with PD1 inhibitor or MEK inhibitor in patients with advanced solid tumors.
Inclusion Criteria:
* Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor. Some cohorts must meet specific expression or gene mutation where indicated
* Sufficient organ function
* Participants must have at least 1 measurable lesion as defined by RECIST v1.1
* Must be able to provide an archived tumor sample
* ECOG performance status score of 0 or 1.
Exclusion Criteria:
* History of cancer that is histologically distinct from the cancers under study
* Active or untreated central nervous system (CNS) metastases
* History of pneumonitis or interstitial lung disease (ILD)
* Has active hepatitis B, hepatitis C infection, HIV
* Any severe and/or uncontrolled medical conditions
* LVEF ≤50%
* QTcF \>470 msec
